CVS Health



By James Owens

How will CVS Grow Revenue?

- -Based on listing prices, spending on prescription pharmaceuticals is projected to rise from \$450 billion in 2016 to \$600 billion by 2021.
- -CVS earns approximately 45% of its revenue from filling prescriptions, which will allow CVS to capitalize from a growing/aging US population.
- -An acquisition of Aetna, which is poised to be approved by the DOJ, would mean the addition of the USA's 3rd largest health insurance company into CVS.

Is Aetna a Good Deal?

- -CVS has its own Pharmacy Benefits Management system, which negotiates drugs prices with pharmaceutical companies and insurers. CVS could incentivize people to pick up prescriptions at their store, for a reduced cost if they keep Aetna health insurance.
- -Aetna can incentivize the use of CVS walk-in clinics, by guaranteeing a lower price and covering that option.
- -CVS is spending \$145 in cash and .8725 CVS shares (\$70 per share), per share of Aetna. This is a 38% premium compared to projected P/E ratios.

Industry Outlook

- While still facing competition from historical rivals like Rite Aid and Walgreens, CVS is now facing pressure from Walmart and Amazon
- After two failed mergers, Rite Aid has sold 1900 locations to Walgreens as it struggles to find a way to compete against larger pharmacy retailers
- Amazon's acquisition of PillPack has allowed the tech giant to gain pharmaceutical licenses in all 50 states, staging the beginning of Amazon's entry into healthcare
- Walgreens has acquired the pharmacy patient prescriptions and inventory of 185 Fred's stores, as smaller M&A deals become more mainstream

Multiples Analysis							
Forward P/E Ratio							
cvs	10.82X	S&P 500	17.3X				
Walgreens	11.48X	S&P 500	17.3X				
Rite Aid	64.0X	S&P 500	17.3X				
	PEG R	atio					
CVS	.98X	S&P 500	1.88X				
Walgreens	1.04X	S&P 500	1.88X				
Rite Aid	16.67X	S&P 500	1.88X				
	EV/ Eb	pitda					
CVS	7.86X	S&P 500	12.3X				
Walgreens	10.38X	S&P 500	12.3X				
Rite Aid	9.12X	S&P 500	12.3X				

INCOME STATEMENT	2016	2017	2018	2019	2020	2021	2022
Revenue Growth (%)	177,526 NA	184,765 4.1%	192,156 4.0%	199,842 4.0%	207,835 4.0%	216,149 4.0%	224,795 4.0%
Cost of Goods Sold % of Sales	148,669 83.7%	156,220 84.6%	161,695 84.1%	168,162 84.1%	174,889 84.1%	181,885 84.1%	189,160 84.1%
Gross Profit % of Sales	28,857 16.3%	28,545 15.4%	30,461 15.9%	31,679 15.9%	32,947 15.9%	34,264 15.9%	35,635 15.9%
Operating Expenses (SG&A) % of Sales	18,491 10.4%	19,028 10.3%	19,902 10.4%	20,698 10.4%	21,526 10.4%	22,387 10.4%	23,282 10.4%
Operating Income (EBIT)	10,366	9,517	10,559	10,981	11,421	11,877	12,352
Interest Expense	1,058	1,041	1,134	918	759	599	440
Pretax Income	9,308	8,476	9,425	10,063	10,662	11,278	11,913
Income Tax Expense	3,317	1,637	1,979	2,113	2,239	2,368	2,502
Tax Rate	NM	NM	21.0%	21.0%	21.0%	21.0%	21.0%
Net Income	5,991	6,839	7,446	7,950	8,423	8,910	9,411
Operating Income (EBIT) D&A	10,366 2,475	9,517 2,479	10,559 2,629	10,981 2,734	11,421 2,843	11,877 2,957	12,352 3,075
EBITDA	12,841	11,996	13,188	13,715	14,264	14,834	15,428

FREE CASH FLOW (FCF)		2018	2019	2020	2021	2022
ЕВІТ		10,559	10,981	11,421	11,877	12,352
Tax		2,217	2,306	2,398	2,494	2,594
Tax Rate		21.0%	21.0%	21.0%	21.0%	21.0%
Tax-Effected EBIT		8,342	8,675	9,022	9,383	9,758
Plus:						
Depreciation		2,629	2,734	2,843	2,957	3,075
Amortization		0	0	0	0	0
Less:						
Capital Expenditures		(1,975)	(2,050)	(2,125)	(2,200)	(2,275)
Change in Working Capital		(858)	(819)	(852)	(886)	(921)
Free Cash Flow		8,137	8,540	8,889	9,254	9,637
WEIGHTED AVERAGE COST OF CAPITAL						
Weighted Average Cost of Capital	9.1%					
Cost of Equity			Cost of	Debt		
Risk Free Rate	3.0%	Cost of Debt			4.5%	
Expected Market Return	11.0%	Tax Rate			21.0%	
Beta	1.03	After Tax Cos	t of Debt		3.6%	
Cost of Equity	11.24%					
E / (D+E)	72.0%	D / (D+E)			28.0%	
PRESENT VALUE OF CASH FLOWS (PV of	of CF)	2018	2019	2020	2021	2022
		Year 1	Year 2	Year 3	Year 4	Year 5
Discount Factor		0.92	0.84	0.77	0.71	0.65
Present Value of Cash Flows		7,459	7,176	6,847	6,535	6,238
Carried to the Transfer	27832 (1175)					
FIRM VALUE: PERPETUITY GROWTH RAT	E METHOD					
Growth Rate in Perpetuity	2.0%					
WACC	PV of 0	CF PV of	Terminal Va	alue <u>I</u>	Firm Value	
9.19			89,771	=	124,026	
Fair Value:	121.83 P/V:	0.65				